AZN241206P72000
- 6.43
- 0.000.00%
AstraZeneca Newsroom
AstraZeneca (AZN.US) and MSD (MRK.US) announce long-term results from phase 3 Olympia clinical trial
Lynparza is a “first-in-class” PARP inhibitor and the first synthetic lethal targeted therapy to target cells/tumors with homologous recombinant repair (HRR) defects (such as cells carrying BRCA1 and/or BRCA2 mutations).
AstraZeneca, Merck Report Positive Long-term Data for Lynparza
AstraZeneca Says 87.5% of Lynparza-treated Patients Alive at Six Years in Trial
Express News | Lynparza Shows Significant Survival Benefit In Early Breast Cancer In OlympiA Phase III Trial; Reduces Risk Of Death By 28% And Recurrence By 35% At Six Years, Becoming First PARP Inhibitor To Improve Survival In Early Breast Cancer
LYNPARZA (Olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase III Trial
Why Astrazeneca (AZN) Is a Top Value Stock for the Long-Term
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
AstraZeneca (AZN) Receives a Hold From Jefferies
Astrazeneca (AZN.US) has achieved breakthrough therapy designation for a potential blockbuster ADC.
Astrazeneca (AZN.US) has a potential blockbuster ADC that has been granted breakthrough therapy designation.
Merck Reports Mixed Results From Keytruda Ovarian Cancer Study
Astrazeneca, Daiichi Sankyo's Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in US
AZN's Bladder Cancer SBLA for Imfinzi Gets FDA's Priority Tag
ASH 2024: AstraZeneca Set to Take a BiTE Out of Follicular Lymphoma Market
Priority FDA Review Given to AstraZeneca's Imfinzi SBLA for MIBC
AstraZeneca, Daiichi Sankyo's Lung Cancer Treatment Receives Breakthrough Designation From US FDA
Datopotamab Deruxtecan Receives FDA Breakthrough Therapy Designation for EGFR-Mutated Lung Cancer
AstraZeneca Reports Positive Results From Phase 3 Trial of Leukemia Combination Formulation
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
AstraZeneca Announced Fixed-duration Calquence Plus Venetoclax Demonstrated Superior PFS Vs. Standard Of Care In Previously Untreated CLL, With 77% Of Patients Progression Free At Three Years In AMPLIFY Phase III Trial At ASH Meeting
Insider Stock Buying Reaches US$2.58m On AstraZeneca